Partner: Precision Cancer Research
Collect and analyze patient samples to understand autoimmune side effects following checkpoint therapy
11-20 of 590
Partner: National Cancer Care Alliance
Collect and analyze patient samples to understand autoimmune side effects following checkpoint therapy
Post: Advice on Charting an Innovative Path Forward for Cell Therapies
Cellular advances in the field of immunotherapy such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocytes are generating great...
Post: Researchers identify three-drug combination that helps curb the growth of deadly type of skin cancer
A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with...
Post: Parker Institute for Cancer Immunotherapy, JDRF and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative
Collaborative funds $10 million in research to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer SAN FRANCISCO and...
Research Project: Autoimmunity and Cancer Immunotherapy
Can we predict and prevent autoimmune disease after immunotherapy? Overview Checkpoint inhibitors changed the face of cancer by extending the lives...
Post: Diabetes, Cancer Organizations Launch $10 Million Research Effort
The Parker Institute for Cancer Immunotherapy, JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust have announced the launch of a $10 million...
Post: A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why
The first two rounds of treatment went off without a hitch. But last November, after receiving a third dose of potent...
Post: Why Novartis’ Jay Bradner thinks CAR T needs disruptive innovation
The race to develop CAR T and related cell therapies into a pillar of cancer care is just starting, according to...
Post: Immunotherapy is fighting cancer but leaving 1% of patients with diabetes – and scientists ‘have no idea why’
Immunotherapies are fast becoming standard cancer treatments But about one percent of patients that get the immune super-charging treatment develop type 1...